Kenvue Inc. (NYSE:KVUE) Shares Acquired by Community Bank N.A.

Community Bank N.A. lifted its position in shares of Kenvue Inc. (NYSE:KVUE) by 53.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 89,532 shares of the company’s stock after acquiring an additional 31,078 shares during the period. Community Bank N.A.’s holdings in Kenvue were worth $1,927,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Empirical Finance LLC acquired a new stake in shares of Kenvue during the 3rd quarter valued at approximately $336,000. UniSuper Management Pty Ltd acquired a new stake in Kenvue in the third quarter worth $35,544,000. Citizens Business Bank acquired a new stake in Kenvue in the third quarter worth $2,507,000. Fifth Third Bancorp increased its position in Kenvue by 35.3% in the fourth quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock worth $5,976,000 after buying an additional 72,435 shares during the period. Finally, Clearbridge Investments LLC increased its holdings in shares of Kenvue by 364.6% during the third quarter. Clearbridge Investments LLC now owns 484,321 shares of the company’s stock valued at $9,725,000 after purchasing an additional 380,071 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of KVUE traded down $0.25 during mid-day trading on Wednesday, hitting $19.13. 22,713,472 shares of the company’s stock were exchanged, compared to its average volume of 16,738,482. The firm has a fifty day moving average of $19.84 and a two-hundred day moving average of $20.15. Kenvue Inc. has a twelve month low of $17.82 and a twelve month high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.28 by $0.03. The company had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. On average, research analysts predict that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 4.18%. The ex-dividend date of this dividend was Tuesday, February 13th.

Analysts Set New Price Targets

A number of research analysts have recently commented on KVUE shares. The Goldman Sachs Group started coverage on Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price target on the stock. Royal Bank of Canada decreased their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. JPMorgan Chase & Co. lowered their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. Sanford C. Bernstein assumed coverage on Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price on the stock. Finally, William Blair initiated coverage on shares of Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $24.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.